Market Access Transformation (MAT) Secures First Institutional Funding Led by Silversmith Capital Partners
1.12.2020 17:00:00 EET | Business Wire | Press release
Market Access Transformation (MAT), a global healthcare company that uses cutting edge technology to automate and modernize how life sciences companies capture mission-critical insights that drive decision-making across the product lifecycle, today announced a $30 million minority investment from Silversmith Capital Partners, a Boston-based growth equity firm. The investment marks the first time MAT has raised outside capital and will be used to expand the company’s team and accelerate innovation of its product offerings.
Founded in 2016, MAT has revolutionized the way Global Payer Market Research is conducted by developing Rapid Payer Response (RPR), the industry’s only on-demand global platform for gathering critical payer insights. In five years, the company has built a client base of more than 45 biopharma and device manufacturers – including all of the Top 10 pharma companies. MAT’s partnership with Silversmith solidifies its market leadership position in providing technology-driven solutions to the healthcare community.
“Providing our clients with new and improved offerings that address unmet needs within healthcare research and analytics has been our primary focus since we started MAT,” said Baiju Aurora, MAT’s CEO and Co-Founder, who along with Co-Founder Paul Howard will continue to lead the company. “We are incredibly proud of what our team has achieved in such a short period of time and are excited to partner with Silversmith as we look to accelerate our product development initiatives.”
RPR is built on the company’s proprietary SaaS platform that enables manufacturers to obtain more robust insights, in 1/3 the time and 1/2 the cost of more traditional, manual-based approaches. RPR is powered by an expansive global payer network – which spans over 40 countries – and leverages a unique payer selection and vetting process. “While RPR has enabled us to deliver technology solutions to a wide variety of pharma companies across the globe, our expert team of pricing and market access specialists drive client engagement and satisfaction,” added Paul Howard.
“One of the biggest challenges life sciences organizations face is gathering payer insights in an agile manner to drive optimal clinical and commercial product strategies as regulatory and market dynamics evolve,” said Brian Peterson, Principal of Silversmith. “What impressed us most about MAT was their platform’s ability to deliver insights in days instead of months, while maintaining industry-leading quality on a global scale. We are thrilled to partner with Baiju, Paul and the entire MAT team, and look forward to working with them as they continue to bring innovative offerings to the market.”
As part of the investment, Brian Peterson and Jim Quagliaroli, Managing Partner of Silversmith, have joined MAT’s Board of Directors, along with Baiju Aurora and Paul Howard.
Choate, Hall & Stewart served as legal counsel to Silversmith Capital Partners and Day Pitney served as legal counsel to MAT.
About Market Access Transformation
With offices in the US, UK, and India, Market Access Transformation specializes in developing cutting edge technologies that enable the healthcare community to gather and exchange insights that assess the real-world potential of their products. MAT’s first product, Rapid Payer Response™ (RPR), is an online platform-based information exchange that allows healthcare manufacturers to secure On-Demand expert insight from the largest and most diverse global payer network in as little as 5 days. For more information about MAT, please visit www.marketaccesstransformation.com.
About Silversmith Capital Partners
Founded in 2015, Silversmith Capital Partners is a Boston-based growth equity firm with $2.0 billion of capital under management. Silversmith’s mission is to partner with and support the best entrepreneurs in growing, profitable technology and healthcare companies. Representative investments include ActiveCampaign, Appfire, Centauri Health Solutions, DistroKid, Impact, LifeStance Health, MediQuant, Panalgo, Unily, Validity, and Webflow. The partners have over 75 years of collective investing experience and have served on the boards of numerous successful growth companies including ABILITY Network, Archer Technologies, Dealer.com, Liazon, Liberty Dialysis, MedHOK, Net Health, Passport Health, SurveyMonkey, and Wrike. For more information about Silversmith, please visit www.silversmith.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005187/en/
Contact information
Kate Castle
Silversmith Capital Partners
P: 617.670.4345
kate@silversmithcapital.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Eaton vahvistaa eurooppalaista tuotantoaan laajentamalla tuotantolaitostaan Itävallassa1.10.2026 10:00:00 EEST | Tiedote
Eaton juhlistaa Itävallassa sijaitsevan Schremsin tuotantolaitoksensa laajennusta 1. lokakuuta 2026. Laajennus vastaa sähköistymisen ja digitalisaation kasvattamaan kysyntään kaikkialla Euroopassa sekä lisää sähköisten suojaus- ja sähkönhallintaratkaisujen alueellista tuotantokapasiteettia. Alle kymmenessä kuukaudessa valmistunut laajennus yhdistää täysin automatisoidun tuotannon, edistyneen digitaalisen integraation ja tuotteiden end-to-end -jäljitettävyyden. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20261001549090/fi/ Eaton expanded manufacturing capacity in Europe for power management solutions in Schrems, Austria. ”Asiakkaat investoivat kaikkialla Euroopassa kriittiseen infrastruktuuriin, joka pitää yritykset toiminnassa, tukee talouskasvua ja vastaa kasvavaan sähkön kysyntään. Tämä laajennus kuvastaa jatkuvia investointejamme tuotantoon, teknologiaan ja osaavaan työvoimaan. Samalla se lisää niiden tuotteiden ja ra
Aegir Insights Launches Next-Generation Energy Intelligence Platform1.10.2026 10:00:00 EEST | Press release
Aegir Insights today announced the launch of its next-generation energy intelligence platform, combining commercial data, expert research and investment modeling in a single environment for investment decisions across onshore wind, offshore wind, solar, energy storage and data centers. The Aegir Platform links the intelligence that informs commercial decisions in renewables: Markets, companies, projects, auctions, supply chains and transactions. Together with analyst research and investment software, it gives the full context to assess where to invest, which assets and counterparties to consider, and what determines their viability. "Energy investment depends on understanding how projects, companies and markets fit together," said Scott Urquhart, CEO of Aegir Insights. "An asset's ownership, auction position, supply chain and route to market all shape its investment case. We connect that commercial context to Aegir's established investment modeling, laying the foundation for renewables
Advanced MRI Imaging Reveals Changes in Muscle Composition and Fat Infiltration During Obesity Treatment1.10.2026 09:55:00 EEST | Press release
As obesity treatment continues to evolve, understanding what happens to muscle during weight loss is becoming increasingly important. At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD),AMRA Medical Chief Scientific Officer Dr. Jennifer Linge will present how advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930545312/en/ Advanced MRI-based analysis can provide a more detailed view of changes in muscle composition during obesity treatment The presentation addresses an increasingly important question in obesity research: what happens to muscle as people lose weight?Understanding muscle composition changes is important because muscle health is about more than muscle size alone. Research using AMRA’s MRI-derived biomarkers has shown that muscle fat infiltration and muscle vo
Ares Strengthens Commitment to Plenitude Through €1 Billion Capital Contribution1.10.2026 09:30:00 EEST | Press release
Ares Management Corporation (NYSE: ARES), a leading global investment manager, announced today that Ares Alternative Credit funds (“Ares”) participated in a reorganization of the shareholding and governance structure of Plenitude through which Ares and Eni S.p.A (“Eni”) upsized their capital contribution by approximately €1.5 billion, of which over €1 billion is attributable to Ares, based on a pre-money equity valuation of Plenitude of €10.75 billion. Following completion of the transaction, Ares holds 26.24% of Plenitude’s share capital, with Eni holding 65.03% and Energy Infrastructure Partners (“EIP”) as an 8.73% shareholder. Ares first invested in Plenitude in 2025, acquiring a 20% stake in the business for approximately €2 billion. This transaction is geared towards strengthening Plenitude’s capital structure and introduces an enhanced governance framework that supports the company’s long-term growth ambitions. Ares and Eni will jointly control Plenitude, with Ares appointing thr
Orifarm Unveils 2031 Strategy to Accelerate Growth Across Europe, With Significant Expansion in Generics1.10.2026 09:10:00 EEST | Press release
With its five-year strategy, Fit to Scale, Orifarm sets out an ambitious path to scale across Europe, including a major expansion of its prescription medicines business from a Nordic footprint to a broader European platform. The strategy aims to double EBITDA to €300m and generate more than €3bn in revenue by 2031, marking the next step in Orifarm's journey as a diversified European pharmaceutical company bringing affordable medicines to more customers, patients and healthcare systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930257993/en/ Orifarm Headquarter, Odense Denmark “As European healthcare systems face rising demand, budget pressures, and supply challenges, Orifarm is uniquely positioned to improve access to affordable medicines and strengthen European supply. Our Fit to Scale strategy is about playing an even bigger role in meeting these needs and taking Orifarm to the next level,” says Mads Fink Eriksen,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom